Publications

Faster and better than a physician?: Assessing diagnostic proficiency of ChatGPT in misdiagnosed individuals with neuromyelitis optica spectrum disorder

Shan K, Patel MA, McCreary M, Punnen TG, Villalobos F, Tardo LM, Horton LA, Sguigna PV, Blackburn KM, Munoz SB, Burgess KW, Moog TM, Smith AD, Okuda DT 2025 Jan 468

Microenhancement as a Biomarker for Cerebral Microbleed in Inflammatory Cerebral Amyloid Angiopathy: Insights From 3D T1 Black-Blood MR Imaging

Shang T, Sguigna PV, Pinho MC, Moore W, Jones E, Subramanian S, Upadhyaya P, Kelley B, Hatanpaa KJ, Raisanen J 2025 Jan 104

Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)

Ren J, Dewey RB, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM 2024 Dec 22

Generative artificial intelligence versus clinicians: Who diagnoses multiple sclerosis faster and with greater accuracy?

Patel MA, Villalobos F, Shan K, Tardo LM, Horton LA, Sguigna PV, Blackburn KM, Munoz SB, Moog TM, Smith AD, Burgess KW, McCreary M, Okuda DT 2024 Oct 90

Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design

Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O 2024 Jan 17

Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Ren J, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM 2023 Dec 21

Subclinical optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease

Nguyen L, Wang CX, Conger DL, Sguigna PV, Singh S, Greenberg BM 2023 Aug 76

A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis

Tardo L, Salter A, Truong-Le MN, Horton L, Blackburn KM, Sguigna PV 2023 Jan 14

Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study

Sguigna PV, Toranian S, Tardo LM, Blackburn KM, Horton LA, Conger D, Meltzer E, Hogan RN, McCreary M, Zee PC, Takahashi JS, Greenberg BM 2023 Jan 9

A cross-sectional natural history study of aspartylglucosaminuria

Goodspeed K, Horton DK, Lowden A, Sguigna PV, Booth T, Wang ZJ, Edgar VB 2022 Sep 63 425-433

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives

Hussain RZ, Sguigna PV, Okai A, Wright C, Madinawala M, Bass AD, Cutter GR, Manouchehri N, Stuve O 2022 Aug 14

Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience

Sguigna PV, Tardo LM, Blackburn KM, Horton LA, Conger DL, Hogan RN, McCreary MC, Greenberg BM 2022 46 375-382

Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus

Sguigna PV, Tardo L, Conger D, Hogan R, Greenberg BM 2021 Nov 430

Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology Population

Sguigna PV, McCreary MC, Conger DL, Graves JS, Benson LA, Waldman AT, Greenberg BM 2021 Mar 41 19-23

Utilization of video oculography to quantify oculomotor dysfunction in anti-DPPX encephalitis: A case study

Blackburn K, Vernino S, Sguigna P 2020 Nov 46

Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings

Perrone CM, Lisak RP, Meltzer EI, Sguigna P, Tizazu E, Jacobs D, Melamed E, Lucas A, Freeman L, Pardo G, Goodman A, Fox EJ, Costello K, Parsons MS, Zamvil SS, Frohman EM, Frohman TC 2019 Jul 6

Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations

Narayan RN, Wang C, Sguigna P, Husari K, Greenberg B 2019 Jan 27 30-33

Retinal architecture and melanopsin-mediated pupillary response characteristics: A putative pathophysiologic signature for the retino-hypothalamic tract in multiple sclerosis

Meltzer E, Sguigna PV, Subei A, Beh SC, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman E 2017 May 74 574-582

Managing Disability in Progressive Multiple Sclerosis

Dubey D, Sguigna P, Stüve O 2016 Jun 18

Acute relapse after initiation of Siponimod in a patient with secondary progressive MS

Hussain R, O’Leary S, Pacheco FM, Zacharias TE, Litvak P, Sguigna P, Marder E, Kia K, Kooner K, Stüve O 2016 Mar 263 606-610

Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8

Jo Y, Lee PC, Sguigna PV, DeBose-Boyd RA 2011 Dec 108 20503-20508

Membrane-associated ubiquitin ligase complex containing gp78 mediates sterol-accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase

Jo Y, Sguigna PV, Debose-Boyd RA 2011 Apr 286 15022-15031